Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zoster vaccine recombinant, adjuvanted (GSK)
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intradermal, Intramuscular
01
Overview
Varicella zoster virus glycoprotein E adjuvanted with AS01B (commercially known as Shingrix) is a non-live, recombinant subunit vaccine developed by GSK for the prevention of herpes zoster (shingles) and its complications, such as postherpetic neuralgia. The vaccine consists of 50 μg of recombinant varicella-zoster virus glycoprotein E (gE) antigen, the most abundant surface protein of the virus, formulated with the liposome-based AS01B adjuvant system containing monophosphoryl lipid A (MPL) and the saponin QS-21. It works by strongly enhancing pre-existing gE-specific CD4+ T-cell and anti-gE antibody responses to overcome age-related decline in immunity. Shingrix was approved by the U.S. FDA in 2017 and is indicated for adults aged 50 years and older, as well as immunocompromised adults aged 18 years and older. Additionally, Leids Universitair Medisch Centrum (LUMC) is evaluating a fractional intradermal dose of the vaccine in a Phase 2-3 trial in the Netherlands to assess non-inferiority to the standard intramuscular dose.
- Brand names
- Shingrix
- Other names
- herpes zoster vaccine (recombinant, adjuvanted)recombinant zoster vaccinevaricella zoster virus glycoprotein E adjuvanted with AS01Bvaricella-zoster virus glycoprotein E adjuvanted with AS01B
02
Targets
TLR4 (Toll-like receptor 4)gE (VZV glycoprotein E)
Beyond the preview
Go deeper on zoster vaccine recombinant, adjuvanted (GSK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zoster vaccine recombinant, adjuvanted (GSK).